{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
<< Return to Main Site
Johns Hopkins University
  • Sign In
  • Live Courses
  • RSS Calendar
  • Online Courses
  • About
  • Contact Us
  • Help
Close Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

JHMI personnel only - click the left button. All others - please login with the email address you used to register with earlier.

Sign in with your Hopkins JHED ID
Sign in with your email and password
Enter your email and password to login:

*
*
Login

New to CloudCME? Create an Account:

Create New Account
Back to Login Provider Forgot Your Password?

Forgot Your Password?







Back to Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Email is required Invalid: Enter valid email address
First Name is required
Last Name is required
Password is required


Password Requirements

  • Must be between 8 and 16 characters in length
  • Must Contain at least 1 upper case character
  • Must Contain at least 1 lower case character
  • Must contain at least 1 numeric character
  • Must contain at least 1 of the following ! * @ # $ % ^ & + =
Confirm password

Passwords must match
Password must be between 8 and 16 characters and contain the following:
•at least 1 upper case character
•at least 1 lower case character
•at least 1 numerical character
•at least 1 special character

  • -- Select Degree --
  • APRN
  • BSN
  • BSRT
  • CCT
  • CNM
  • CRNA
  • CRNP
  • CTR
  • CVT
  • DDS
  • DMD
  • DNP
  • DO
  • DPM
  • DPT
  • EMT
  • EMT-P
  • FRCA
  • JD
  • LCSW
  • LNM
  • LPN
  • MA
  • MBBS
  • MBChB
  • MD
  • MD, JD
  • MD, MBA
  • MD, MPH
  • MD, PhD
  • MD, ScM
  • MPH
  • MSN
  • MSPH
  • MSW
  • None
  • NP
  • OD
  • OT
  • Other
  • OTR
  • PA-C
  • PharmD
  • PhD
  • PT
  • RCES
  • RD
  • RN
  • RN, BSN
  • RT
  • RTT
  • SLP
Degree is required
Please enter your degree:
You must enter a degree

Profession is required




Back to Login
Close Search Site Search: Enter your search terms in the field below to view results.

please enter a term to search
Close Specialties
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

80048634 - OncologyConsults: Optimizing the Use of Targeted Therapies in First and Subsequent Lines of Treatment for ALK-Positive Non-Small Cell Lung Cancer

  • Overview
  • Faculty
  • Tests


Date & Location
Monday, April 15, 2019, 12:00 AM - Wednesday, April 15, 2020, 12:00 AM

Target Audience
Specialties - Nurse Practitioner, Nursing, Oncology, Physician Assistant

Overview

An estimated 234,030 new cases of lung cancer will be diagnosed in the United States in 2018. As the major type, non-small cell lung cancer (NSCLC) represents about 80% to 85% of lung cancers. It is therefore critical for oncology healthcare practitioners (HCPs) to be able to appropriately utilize novel treatment options that can target locally advanced or metastatic NSCLC. The discovery of anaplastic lymphoma kinase (ALK) rearrangements as oncogenic driver mutations has resulted in the development of targeted tyrosine kinase inhibitors against ALK (ALKis). The ALKis have shifted the standard of care for patients with metastatic NSCLC harboring specific ALK rearrangements (designated ALK+ NSCLC). Therefore, for the benefit of patients with this devastating disease, oncology HCPs require timely, comprehensive continuing education that can guide them in safely and effectively incorporating these novel therapeutic options into their practices.

Release date: Monday, April 15, 2019 

Expiration date: April 15, 2020.

OncologyConsults.com is a learning portal that will address knowledge, competence and clinical practice gaps among clinicians who care for patients with cancers.

Weblink:
https://www.oncologyconsults.com/Home/CEData?id=793


Objectives
Upon completion of this activity, the learner will demonstrate the ability to:

  1. Describe the clinical relevance of ALK genetic testing on treatment-decision-making in NSCLC and the rationale for ALKi therapy.
  2. Assess the efficacy, safety, and clinical utility of 1st-line ALKis in patients with ALK+ NSCLC.
  3. Evaluate subsequent line treatment options upon acquired resistance to ALKi.
  4. Develop individualized treatment protocols for patients with ALK+ NSCLC based on the most up-to- date clinical data regarding first/subsequent lines of treatment.

Accreditation
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Keywords: ONLINE

Rebecca Barshick, MSN
Nurse Educator
IJHN
Lisa Chester, MBA
Johns Hopkins School of Medicine
David S Ettinger, MD
Alex Grass Professor of Oncology
Kimmel Cancer Center at Johns Hopkins
Susan Gearhart, MD
Assoicate Professor
Johns Hopkins University School of Medicine
Daniel Guinee,, MBA
Stefanie Houseknecht, PharmD
Kristen A Marrone, MD
Assistant Professor of Oncology
Johns Hopkins University School of Medicine
Raven Minervino, MA
MiKaela M Olsen, MS
Johns Hopkins Hospital
Adrienne Roser
Director of Accreditation
ASiM Ce, LLC

OncologyConsults: Optimizing the Use of Targeted Therapies in First and Subsequent Lines of Treatment for ALK-Positive Non-Small Cell Lung Cancer

Contact Us:
410-955-2959
Or by email: [email protected]

link to disclosure form

New Activity Request Form

Hopkins CME logo
http:// www.hopkinsmedicine.org
Facebook link   Twitter link   LinkedIn link

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved. Privacy Policy